What Recombinant Capital does

Clarivate Plc is a publicly traded (NYSE: CLVT) global intelligence company that provides proprietary data, analytics, workflow software, and expert services across three segments: Life Sciences & Healthcare, Intellectual Property, and Academia & Government. The company is headquartered in Philadelphia with regional offices in London, Barcelona, and Boston, and an operational footprint spanning the US, UK, Spain, China, Japan, and Korea. Its core Life Sciences portfolio centers on the Cortellis suite — Deals Intelligence (135k+ pharma deals, 15.5k+ with contracts, 9.6k unredacted), Competitive Intelligence, Clinical Trials Intelligence, Drug Discovery, Regulatory, and CMC modules — complemented by DRG disease/market intelligence and BioWorld news. The Intellectual Property portfolio is anchored by Derwent (Derwent World Patents Index covering 70m+ human-authored invention summaries across 60 patent authorities, plus Patent Search, Analytics, Monitor, Sequence Search, Chemistry Research, incoPat, Data Analyzer, and APIs) and CompuMark trademark solutions (SAEGIS, Brand Landscape Analyzer, Trademark Watch, plus Darts-ip case law). IP management software includes IPfolio, Inprotech, and FoundationIP. The Academia & Government segment comprises Web of Science, InCites, Journal Citation Reports, EndNote, ProQuest, and Ex Libris/Innovative library platforms (Alma, Primo, Leganto, Sierra).

The company's core technology is an AI-powered intelligence layer built atop proprietary, human-curated data assets. Notable components include purpose-built AI models trained by in-house staff (colBERT for patent search, LLM for patent classification), Cortellis Deals Predictive Analytics (trained on thousands of real-world pharma deals to forecast deal values and success probabilities by indication, phase, and deal type), and RiskMark — a 2025 product combining predictive and generative AI with 172.5m trademark records and 5m+ court decisions to produce risk scores and legally grounded draft arguments. Data feeds and APIs are used by 40+ national patent and trademark offices, indicating platform-level distribution beyond end-customer SaaS.

The business model is multi-stream: subscription SaaS for intelligence platforms (Cortellis, Derwent, CompuMark, Web of Science), professional services (270+ patent search professionals, IP recordals, annuities, docketing, translations), and enterprise data feeds/APIs for internal analytics integration. Pricing is quote-based and not publicly disclosed. Go-to-market is enterprise field sales targeting pharma/biotech business development and licensing teams, corporate IP and trademark departments, IP law firms, and academic/government institutions, supported by content marketing, webinars, podcasts, and industry events. Customer concentration is moderate, anchored by leading global pharma, top global brands (9 of 10 Interbrand 2025 best global brands use CompuMark), major IP law firms, and academic institutions, with recurring subscriptions providing revenue visibility. Note: the input data identifies the company as "Recombinant Capital" but contains no Recombinant Capital-specific facts; all substantive evidence pertains to Clarivate Plc.

Name

Recombinant Capital

Legal name

Clarivate Plc

Website

https://recap.com

Company type

Public

Founded year

1988

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Clarivate Plc is a publicly traded global intelligence company providing AI-powered data, analytics, and expert services across life sciences, intellectual property, and academia for pharma, biotech, IP law firms, and academic institutions.

Ownership category

akta.pro rank

Product category

Intellectual Property and Life Sciences Intelligence Software

NAICS

Software Publishers (513210)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

IP Management, Patents & Trademark Software (BPAEAPAN)

akta.pro secondary industry

Customer Churn, CLV & Retention Intelligence (HDAAAHAC)

Keywords

• Biopharma deals intelligence
• Patent analytics software
• Trademark risk assessment
• IP management platforms
• Research analytics software

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Subscription-based SaaS Access: Annual subscription access to intelligence platforms including Cortellis Deals Intelligence, Derwent Patent Search, CompuMark trademark tools, and other analytics platforms. Provides continuous access to databases, analytics, and predictive tools with tiered pricing based on organization size and access level
2. Professional Services: Expert consulting and services including patent search services (270+ search professionals), patent analytics services, IP management consulting, docketing, recordals, translations, and administrative support for IP workflows
3. Data Feeds and APIs: Bulk data delivery via feeds or APIs for enterprise analytics, dashboards and applications powered by trusted biopharma deals intelligence and patent data

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Recombinant Capital sells subscription-based AI-powered intelligence platforms and professional services across biopharma deals (Cortellis Deals Intelligence), patent research (Derwent), trademark clearance and watch (CompuMark, RiskMark), IP management software (IPfolio, Inprotech), academic research analytics (Web of Science, ProQuest), and library services (Ex Libris Alma, Primo). Revenue is generated primarily through annual subscriptions, data feeds/APIs, and expert services delivered to enterprise customers in life sciences, IP law, and academia.

Product overview

Clarivate is a multi-segment intelligence company offering a broad portfolio of data, analytics, workflow solutions, and expert services across three primary segments: Life Sciences & Healthcare (Cortellis, DRG, BioWorld), Intellectual Property (Derwent, CompuMark, Darts-ip, IP management software), and Academia & Government (Web of Science, ProQuest, Ex Libris/Innovative library platforms). The Life Sciences portfolio centers on Cortellis — a suite of pharma/biotech intelligence products spanning deals intelligence (Cortellis Deals Intelligence), competitive intelligence, drug discovery, clinical trials, regulatory intelligence, CMC intelligence, and product intelligence — complemented by DRG market assessment and epidemiology tools, and BioWorld biotech news. The IP portfolio is anchored by Derwent Patent Intelligence (including Derwent Patent Search, Derwent Patent Analytics, Derwent Patent Monitor, Derwent Sequence Search, Derwent Chemistry Research, Derwent World Patents Index, Derwent Data Analyzer, incoPat, and Derwent Patent Data APIs) and CompuMark trademark solutions (SAEGIS, Brand Landscape Analyzer, Trademark Watch Analyzer, RiskMark, TrademarkVision, DesignVision, Darts-ip). IP management software includes IPfolio, Inprotech, FoundationIP, and others. The Academia & Government segment includes Web of Science, InCites, Journal Citation Reports, Essential Science Indicators, EndNote, RefWorks, Pivot-RP, Esploro, Master Journal List, ProQuest platforms, and Ex Libris/Innovative library management systems (Alma, Primo, Leganto, Sierra, Polaris, Vega, Rapido, Rialto).

Differentiator

Problem solved

Functional benefit

Brands

• Cortellis: Pharma deals intelligence and competitive intelligence platform providing comprehensive data on licensing, partnering, and M&A transactions
• Derwent
• CompuMark
• BioWorld
• Darts-ip
• RiskMark
• ProQuest
• Ex Libris
• Web of Science
• EndNote
• RefWorks

Products and services

• Cortellis Deals Intelligence Biopharma deals intelligence platform providing comprehensive data and AI-powered analytics to evaluate, negotiate, and execute partnering, licensing, and M&A transactions. Covers 135k+ deals including early-stage deals, M&A, and 15.5k+ deals with contracts (9.6k unredacted). Includes first-in-class predictive deal value analytics for biotech and pharma BD&L teams.
• Derwent Patent Intelligence Comprehensive patent search and analytics platform combining AI-powered tools with 70m+ human-authored Derwent invention summaries across 60 patent authorities. Used by corporate IP teams, patent attorneys, and patent offices for patentability, freedom-to-operate, invalidity, and portfolio analysis.
• CompuMark Comprehensive trademark intelligence suite covering the full trademark lifecycle — from screening and search (SAEGIS, Clearance Full Search, Brand Landscape Analyzer) to watching (Trademark Watch, Trademark Watch Analyzer), case law insights, and portfolio maintenance. Covers 168m+ trademark records, 500m+ global company names, and 187 trademark databases. Used by corporate trademark teams and brand-protection professionals.
• RiskMark AI-powered trademark risk assessment tool combining predictive and generative AI with CompuMark trademark data and Darts-ip global case law data to evaluate trademark conflicts based on precedent. Generates risk scores, legally grounded draft arguments, and case law insights across visual, phonetic, semantic, and goods/services similarity dimensions.
• Derwent Patent Data and APIs Patent data feeds and APIs providing direct, scalable access to high-quality, enriched global patent data for enterprise AI, workflow, and analytics platforms. Trusted by 40 global patent and trademark offices.
• Web of Science Research discovery and citation indexing platform covering scholarly literature across sciences, social sciences, arts, and humanities with Web of Science Core Collection, APIs, and XML data for academic and government institutions.
• ProQuest Academic content platform providing essential content across disciplines and formats including ProQuest One Academic, ProQuest Dissertations & Theses, Ebook Central, ProQuest News & Newspapers, and Alexander Street academic video for libraries and academic institutions.
• Ex Libris Alma Cloud-based library services platform providing integrated library management for academic institutions with Ex Libris Open Platform for integrations.
• IPfolio Cloud-based IP management platform for corporate IP teams providing portfolio management, workflow automation, and deadline tracking.
• Derwent Patent Search Services Expert patent research services for high-confidence patentability, freedom to operate, and validity decisions delivered by 270+ search professionals.
• BioWorld Award-winning biotech and biopharma news platform providing actionable intelligence on the most innovative therapeutics and medical technologies in development.
• Cortellis Competitive Intelligence Comprehensive pipeline and pharma competitive intelligence platform enabling critical portfolio decisions across the drug lifecycle.

Quantifiable outcome

• Near-instant trademark conflict assessment replacing hours of manual research
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration13 records

AI capability10 records

Feature5 records

Scale indicators14 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Thomson Reuters: Operates Westlaw and other legal/regulatory intelligence products serving the same enterprise legal and corporate counsel buyers as Clarivate's IP and regulatory segments, with comparable enterprise SaaS economics and AI-augmentation roadmap.
• Wolters Kluwer: Provides expert information and software solutions across legal, regulatory, tax, and healthcare — directly comparable to Clarivate's IP, regulatory, and life sciences intelligence franchises with a similar vertical SaaS model and global enterprise footprint.
• LexisNexis (RELX): RELX's LexisNexis division is the closest broad incumbent peer: it competes head-on in legal and IP research (LexisNexis PatentSight, LexisNexis IP), shares a subscription SaaS model, and targets the same enterprise legal and corporate IP buyer. It is broader, with adjacent risk and scientific segments.
• S&P Global (including IHS Markit): Comparable as a global data, analytics, and intelligence incumbent with subscription-based enterprise sales and adjacent exposure to financial, commodity, and industry intelligence — similar customer profile to Clarivate's enterprise accounts.

Direct peers

• Anaqua: Direct competitor in IP management software (Anaqua Platform, AQX) serving corporate IP teams and law firms — overlaps with Clarivate's IPfolio, Inprotech, and FoundationIP product lines.
• IQVIA: Direct competitor in life sciences intelligence: IQVIA's R&D and deal analytics overlap with Cortellis, DRG, and BioWorld for pharma BD&L, competitive intelligence, and clinical trial decision-making.

Emerging players

• PatSnap: AI-native patent analytics and intelligence platform competing with Derwent and incoPat — represents the emerging wave of faster-moving challengers applying LLMs and graph analytics to patent search.
• PitchBook (Morningstar): Deals and private capital intelligence platform comparable to Cortellis Deals Intelligence for transaction data, valuation benchmarking, and M&A analytics — overlaps in customer use cases for dealmaking.
• Minesoft / PatInfo: Patent and trademark intelligence specialist with PatBase and similar products, overlapping with Clarivate's Derwent and CompuMark franchises for IP and brand protection teams.

Regional players

• EBSCO Information Services: Adjacent competitor in academic and library content/research intelligence, overlapping with Clarivate's Academia & Government segment (Web of Science, ProQuest) for institutional library and research customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/clarivate
• Facebookfacebook.com/clarivate
• LinkedInlinkedin.com/company/thomson-reuters-recap
• Instagraminstagram.com/lifeatclarivate

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Recombinant Capital